Study of 64Cu-LNTH-1363S in Sarcoma or GI Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new imaging agent, 64Cu-LNTH-1363S, to see if it can find certain sarcomas and gastrointestinal cancers. The goal is to help doctors better see where your cancer is and plan the best treatment. You may be eligible if you have a sarcoma or a GI cancer and are willing to have a tumor tissue sample taken.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years or older (and weigh at least 55 kg if between 15 and 18 years old).
- You have a type of sarcoma or a gastrointestinal cancer (like esophageal, stomach, pancreatic, or colorectal cancer).
- Your cancer is suspected to have a protein called FAP, which the study drug targets.
- You are willing to provide a tumor tissue sample (from a past biopsy or a new one).
- Your kidneys work well enough (based on a blood test).
- If you could become pregnant or father a child, you agree to use effective birth control during the study and for 28 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
This trial uses a special imaging agent called SLR-108 to take detailed PET scans of your cancer. It aims to see if this scan can help doctors better understand metastatic solid tumors that have grown after previous treatment.
Hear when a new Metastatic Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.